PGWM
ESPR

Parisi Gray Wealth Management’s Esperion Therapeutics ESPR Stock Holding History

Parisi Gray Wealth Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-180
Closed -$4K – 264
2021
Q2 		$4K Buy
+180
New +$4.33K ﹤0.01% 519
2019
Q2 		– Sell
-180
Closed -$7K – 219
2019
Q1 		$7K Hold
180
– – ﹤0.01% 414
2018
Q4 		$8K Hold
180
– – 0.01% 416
2018
Q3 		$8K Hold
180
– – ﹤0.01% 430
2018
Q2 		$8K Hold
180
– – 0.01% 436
2018
Q1 		$12K Hold
180
– – 0.01% 405
2017
Q4 		$12K Buy
+180
New +$9.69K 0.01% 417

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Parisi Gray Wealth Management's ESPR Position: Q3 2021 in Review

Parisi Gray Wealth Management sold out of Esperion Therapeutics (ESPR) in Q3 2021, closing a stake of 180 shares — an estimated $4K sold.

Parisi Gray Wealth Management first reported a position in ESPR in Q4 2017 and held it in 7 quarters. The position peaked at $12K in Q1 2018. 139 funds tracked by Wall St. Rank hold ESPR as of Q3 2021.

  • Parisi Gray Wealth Management reported no remaining Esperion Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Parisi Gray Wealth Management sold 180 Esperion Therapeutics shares in Q3 2021, an estimated $4K.
  • Parisi Gray Wealth Management first reported a position in Esperion Therapeutics in Q4 2017 and held it in 7 quarters.
  • Parisi Gray Wealth Management's Esperion Therapeutics position peaked at $12K in Q1 2018.
  • 139 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2021.

Based on Parisi Gray Wealth Management's 13F filing for Q3 2021, filed 16 Nov 2021.